TCT 2019—Spotlight on cellular therapy with Miguel-Angel Perales, MD


  • Yael Waknine
  • Univadis
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Miguel-Angel Perales, MD, Deputy Chief, Adult Bone Marrow Transplant Service and Director, Adult Bone Marrow Transplantation Fellowship Program at Memorial Sloan Kettering Cancer Center in NY, NY was interviewed by Yael Waknine of Univadis at the TCT meeting held February 20-24, 2019, in Houston, TX.

  • Cell therapy has taken on a much bigger role in this TCT meeting.
  • Natural killer (NK) cell therapy is yielding promising results.
  • Chimeric antigen receptor (CAR) T-cell real-world studies are reproducing the paradigm-shifting results observed in clinical trials.
  • CAR T-cells are now being studied in combination with targeted therapies and immune checkpoint inhibitors.
  • CAR T-cell regulatory approvals are anticipated for the treatment of myeloma and lymphoma.
  • The next step will be to optimize CAR T-cell safety and efficacy.
  • The centralized Cellular Immunotherapy Data Resource (CIDR) registry is being formed to accelerate discovery of new targets and evaluate novel therapies.

Highlights vom TCT-Kongress 2019